| pubmed-article:21596889 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21596889 | lifeskim:mentions | umls-concept:C0017636 | lld:lifeskim |
| pubmed-article:21596889 | lifeskim:mentions | umls-concept:C0007587 | lld:lifeskim |
| pubmed-article:21596889 | lifeskim:mentions | umls-concept:C0037083 | lld:lifeskim |
| pubmed-article:21596889 | lifeskim:mentions | umls-concept:C0033414 | lld:lifeskim |
| pubmed-article:21596889 | lifeskim:mentions | umls-concept:C1149190 | lld:lifeskim |
| pubmed-article:21596889 | lifeskim:mentions | umls-concept:C1416386 | lld:lifeskim |
| pubmed-article:21596889 | lifeskim:mentions | umls-concept:C1710082 | lld:lifeskim |
| pubmed-article:21596889 | lifeskim:mentions | umls-concept:C0205227 | lld:lifeskim |
| pubmed-article:21596889 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:21596889 | pubmed:dateCreated | 2011-7-8 | lld:pubmed |
| pubmed-article:21596889 | pubmed:abstractText | Glioblastoma multiforme (GBM) is one of the most lethal forms of cancer, with a survival rate of only 13% to 27% within 2 years of diagnosis despite optimal medical treatment. We hypothesize that the presence of a unique IL-13R?2 decoy receptor prevents GBM apoptosis. This receptor has a high affinity for interleukin-13 (IL-13), binds the cytokine, and competitively inhibits the intracellular signaling cascade initiated by IL-13. In cells lacking the IL-13R?2 decoy receptor, IL-13 initiates the production of 15-lipoxygenase-1 (15-LOX-1), which has been implicated in cellular apoptosis. Our group and others have shown that induction of 15-LOX-1 correlates with tumor cell death in colorectal, pancreatic, and prostate cancer. How 15-LOX-1 induces apoptosis remains unclear. Preliminary evidence in GBM cells implicates an apoptotic process mediated by PPAR?. 15-LOX-1 metabolites can modulate PPAR? and activation of PPAR? can suppress tumor growth. We hypothesize that in GBM, IL-13 can induce 15-LOX-1, which regulates cell apoptosis via signaling through PPAR? and that expression of IL-13R?2 prevents apoptosis and contributes to tumor growth. Our in vitro and in vivo data support this. Knocking down IL-13R?2 with short interfering RNA dramatically induces 15-LOX-1 expression, promotes apoptosis, and reduces GBM tumor growth in vivo. These findings identify a mechanism for eliminating the blockade of endogenous IL-13 signaling and for promotion of apoptosis, and characterize a role for 15-LOX-1 in GBM apoptosis. Identifying a mechanistic pathway that can be targeted for pharmacologic intervention will have applied implications to developing novel and effective treatments of GBM. | lld:pubmed |
| pubmed-article:21596889 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21596889 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21596889 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21596889 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21596889 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21596889 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21596889 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21596889 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21596889 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21596889 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21596889 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21596889 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21596889 | pubmed:issn | 1538-8514 | lld:pubmed |
| pubmed-article:21596889 | pubmed:author | pubmed-author:LinN SNS | lld:pubmed |
| pubmed-article:21596889 | pubmed:author | pubmed-author:HsiLinda CLC | lld:pubmed |
| pubmed-article:21596889 | pubmed:author | pubmed-author:KunduSumanS | lld:pubmed |
| pubmed-article:21596889 | pubmed:author | pubmed-author:VogelbaumMich... | lld:pubmed |
| pubmed-article:21596889 | pubmed:author | pubmed-author:CathcartMarth... | lld:pubmed |
| pubmed-article:21596889 | pubmed:author | pubmed-author:PalomoJuanJ | lld:pubmed |
| pubmed-article:21596889 | pubmed:author | pubmed-author:FiccoRyanR | lld:pubmed |
| pubmed-article:21596889 | pubmed:copyrightInfo | © 2011 American Association for Cancer Research. | lld:pubmed |
| pubmed-article:21596889 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21596889 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:21596889 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21596889 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21596889 | pubmed:pagination | 1149-60 | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:meshHeading | pubmed-meshheading:21596889... | lld:pubmed |
| pubmed-article:21596889 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21596889 | pubmed:articleTitle | Silencing IL-13R?2 promotes glioblastoma cell death via endogenous signaling. | lld:pubmed |
| pubmed-article:21596889 | pubmed:affiliation | Department of Cell Biology, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio 44195, USA. hsil@ccf.org | lld:pubmed |
| pubmed-article:21596889 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21596889 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21596889 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:3598 | entrezgene:pubmed | pubmed-article:21596889 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21596889 | lld:entrezgene |
